| Pulmonary arterial hypertension
WINREVAIR vs Tyvaso
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Winrevair vs Tyvaso with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTyvaso has a higher rate of injection site reactions vs Winrevair based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tyvaso but not Winrevair, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Winrevair
Tyvaso
At A Glance
Subcutaneous
Every 3 weeks
Activin signaling inhibitor
Oral inhalation
4 times daily
Prostacyclin analogue
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
- Pulmonary hypertension due to interstitial lung disease
Dosing
Pulmonary arterial hypertension Starting dose 0.3 mg/kg subcutaneously every 3 weeks; target dose 0.7 mg/kg subcutaneously every 3 weeks after verifying acceptable hemoglobin and platelet count. Check hemoglobin and platelets before each dose for the first 5 doses or longer if values are unstable.
Pulmonary arterial hypertension, Pulmonary hypertension due to interstitial lung disease Initial dose: 3 breaths (18 mcg) per treatment session 4 times daily via the Tyvaso Inhalation System; if not tolerated, reduce to 1-2 breaths. Increase by 3 breaths per session every 1-2 weeks as tolerated to target maintenance dose of 9-12 breaths per session 4 times daily.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, erythema, increased hemoglobin
Serious Erythrocytosis, severe thrombocytopenia (platelet count <50,000/mm3), serious bleeding, intrapulmonary right-to-left shunting
Postmarketing Pericardial effusion
Most common (>=4%) Cough, headache, throat irritation/pharyngolaryngeal pain, nausea, flushing, syncope
Serious Decrease in systemic blood pressure, bleeding
Postmarketing Angioedema
Pharmacology
Sotatercept-csrk is an activin signaling inhibitor that binds to activin A and other TGF-beta superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in pulmonary arterial hypertension.
Treprostinil is a prostacyclin analogue whose major pharmacologic actions are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Winrevair
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (9/12) · Qty limit (9/12)
Tyvaso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Winrevair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (2/8)
Tyvaso
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Winrevair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Tyvaso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Merck Access Co-pay Assistance: WinrevairCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
WinrevairView full Winrevair profile
TyvasoView full Tyvaso profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.